Source: Reunion Neuroscience (formerly Field Trip Health)
  • Field Trip Health (FTRP) will release financial results for the fiscal second quarter after market close on Monday, November 15, 2021
  • The company will conduct a conference call and webcast to discuss its results on Tuesday, November 16 at 8:30 am ET
  • A live webcast of the conference call can be accessed via the Events and Presentations section of the Field Trip Health Investor Relations website
  • Field Trip is a global leader in the development and delivery of psychedelic therapies
  • Field Trip Health Ltd. (FTRP) opened trading at C$6.60 per share

Field Trip Health (FTRP) will release financial results for the fiscal second quarter ended September 30, 2021, after market close on November 15.

The company will conduct a conference call and webcast to discuss its results on Tuesday, November 16 at 8:30 am ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13724604.

A live webcast of the conference call can be accessed via the Events and Presentations section of the Field Trip Health Investor Relations website here.

For those unable to attend the live call, a telephonic replay will be available until 11:59 pm ET on Tuesday, November 30, 2021. To access the replay of the call dial 1-844-512-2921 (within the U.S.) or 1-412-317-6671 (outside the U.S.) and provide conference ID 13724604.

An archived copy of the webcast will be available on the Events and Presentations section of the Field Trip Health Investor Relations website after the conclusion of the call.

Field Trip is a global leader in the development and delivery of psychedelic therapies.

Field Trip Health Ltd. (FTRP) opened trading at C$6.60 per share.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.